Oculis (NASDAQ:OCS) Shares Gap Up Following Analyst Upgrade

Oculis Holding AG (NASDAQ:OCS) gapped up before the market opened on Thursday after HC Wainwright raised their price target on the stock from $29.00 to $32.00. The stock had previously closed at $18.02, but opened at $18.55. HC Wainwright currently has a buy rating on the stock. Oculis shares last traded at $18.35, with a volume of 2,721 shares traded.

Several other brokerages have also recently commented on OCS. Robert W. Baird increased their price target on shares of Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a research report on Thursday, March 13th. Chardan Capital restated a “buy” rating and set a $28.00 price objective on shares of Oculis in a research note on Thursday.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of OCS. Bellevue Group AG acquired a new stake in Oculis during the fourth quarter worth about $170,000. XTX Topco Ltd bought a new position in shares of Oculis during the fourth quarter valued at approximately $225,000. Geode Capital Management LLC raised its position in shares of Oculis by 12.0% during the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock worth $284,000 after purchasing an additional 1,800 shares during the period. Citadel Advisors LLC bought a new stake in shares of Oculis in the 4th quarter worth approximately $389,000. Finally, Bank of America Corp DE boosted its position in Oculis by 58.2% during the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock valued at $493,000 after purchasing an additional 10,667 shares during the period. 22.30% of the stock is currently owned by institutional investors.

Oculis Stock Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The stock has a 50 day moving average of $18.87 and a 200 day moving average of $17.94. The stock has a market capitalization of $797.70 million, a P/E ratio of -9.47 and a beta of 0.19.

Oculis (NASDAQ:OCS) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.28). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. Equities analysts predict that Oculis Holding AG will post -2.09 EPS for the current year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.